Literature DB >> 19471658

Major clinical research advances in gynecologic cancer 2008.

Kidong Kim1, Seok-Cheol Choi, Sang-Young Ryu, Jae Weon Kim, Soon-Beom Kang.   

Abstract

In this review, we summarized 14 major clinical advances in gynecology which occurred in 2008. For cervical cancer, clinical impact of HPV vaccine, prognostic value of imaging during radiotherapy, and oncologic/obstetric outcomes of fertility-sparing surgery were chosen. For uterine cancer, optimal method of adjuvant radiotherapy in intermediate-risk patients, extent of lymph node dissection, outcome of robot-assisted staging surgery, new standard chemotherapy regimen for leiomyosarcoma were selected. For ovarian cancer, recent changes in adjuvant therapy, feasibility of neoadjuvant chemotherapy, prediction of optimal secondary cytoreduction, studies on new biomarkers, advances in screening and treatment of women with BRCA mutations were included. For other cancers, the safety of sentinel lymph node dissection in vulvar cancer and chemotherapy regimens for low-risk gestational trophoblastic tumors were reviewed.

Entities:  

Keywords:  Biomedical research; Gynecology; Urogenital neoplasms

Year:  2008        PMID: 19471658      PMCID: PMC2676488          DOI: 10.3802/jgo.2008.19.4.209

Source DB:  PubMed          Journal:  J Gynecol Oncol        ISSN: 2005-0380            Impact factor:   4.401


  42 in total

1.  Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

Authors:  F M Muggia; P S Braly; M F Brady; G Sutton; T H Niemann; S L Lentz; R D Alvarez; P R Kucera; J M Small
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

2.  Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica.

Authors:  G Bolis; N Colombo; S Pecorelli; V Torri; S Marsoni; C Bonazzi; S Chiari; G Favalli; G Mangili; M Presti
Journal:  Ann Oncol       Date:  1995-11       Impact factor: 32.976

3.  A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer.

Authors:  I Jacobs; D Oram; J Fairbanks; J Turner; C Frost; J G Grudzinskas
Journal:  Br J Obstet Gynaecol       Date:  1990-10

4.  Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.

Authors:  Dennis S Chi; Kristina McCaughty; John P Diaz; Jae Huh; Sarah Schwabenbauer; Amanda J Hummer; Ennapadam S Venkatraman; Carol Aghajanian; Yukio Sonoda; Nadeem R Abu-Rustum; Richard R Barakat
Journal:  Cancer       Date:  2006-05-01       Impact factor: 6.860

5.  Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group.

Authors:  F B Stehman; B N Bundy; P M Dvoretsky; W T Creasman
Journal:  Obstet Gynecol       Date:  1992-04       Impact factor: 7.661

6.  Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.

Authors:  June Y Hou; Michael G Kelly; Herbert Yu; Jessica N McAlpine; Masoud Azodi; Thomas J Rutherford; Peter E Schwartz
Journal:  Gynecol Oncol       Date:  2007-01-18       Impact factor: 5.482

7.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Authors:  Richard G Moore; D Scott McMeekin; Amy K Brown; Paul DiSilvestro; M Craig Miller; W Jeffrey Allard; Walter Gajewski; Robert Kurman; Robert C Bast; Steven J Skates
Journal:  Gynecol Oncol       Date:  2008-10-12       Impact factor: 5.482

8.  European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

Authors:  E A Eisenhauer; W W ten Bokkel Huinink; K D Swenerton; L Gianni; J Myles; M E van der Burg; I Kerr; J B Vermorken; K Buser; N Colombo
Journal:  J Clin Oncol       Date:  1994-12       Impact factor: 44.544

9.  Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging.

Authors:  Andrea Mariani; Sean C Dowdy; William A Cliby; Bobbie S Gostout; Monica B Jones; Timothy O Wilson; Karl C Podratz
Journal:  Gynecol Oncol       Date:  2008-03-04       Impact factor: 5.482

10.  Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer.

Authors:  Vanessa N Harry; Scott I Semple; Fiona J Gilbert; David E Parkin
Journal:  Gynecol Oncol       Date:  2008-09-06       Impact factor: 5.482

View more
  5 in total

1.  Major clinical research advances in gynecologic cancer in 2010.

Authors:  Dong Hoon Suh; Jae Weon Kim; Kidong Kim; Soon-Beom Kang
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

2.  Major clinical research advances in gynecologic cancer 2009.

Authors:  Kidong Kim; Sang-Young Ryu
Journal:  J Gynecol Oncol       Date:  2009-12-28       Impact factor: 4.401

3.  TALEN based HPV-E7 editing triggers necrotic cell death in cervical cancer cells.

Authors:  Sumitra Shankar; Deepti Prasad; Rahul Sanawar; Ani V Das; M Radhakrishna Pillai
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

Review 4.  Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.

Authors:  Dong Hoon Suh; Miseon Kim; Kidong Kim; Hak Jae Kim; Kyung Hun Lee; Jae Weon Kim
Journal:  J Gynecol Oncol       Date:  2017-03-24       Impact factor: 4.401

5.  Temporal Changes in Subcutaneous Fibrosis in Patients with Lower Extremity Lymphedema Following Surgery for Gynecologic Cancer: A Computed Tomography-Based Quantitative Analysis.

Authors:  Soyoung Lee; Dong Gyu Lee; Kyoung Tae Kim
Journal:  Diagnostics (Basel)       Date:  2022-08-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.